{"prompt": "['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Investigator safety reports are prepared for suspected unexpected serious adverse', 'reactions according to local regulatory requirements and GSK policy and are forwarded', 'to investigators as necessary.', 'An investigator who receives an investigator safety report describing a SAE(s) or other', 'specific safety information (e.g., summary or listing of SAEs) from GSK will file it with', 'the IB and will notify the IRB/IEC, if appropriate according to local requirements.', '7.4.1.8.', 'Additional Adverse Event (AE) Reporting Requirements for Canadian', 'investigators', 'Health Canada requires pharmaceutical manufacturers to expeditiously report domestic', 'cases of unusual failure in efficacy (UFIE) for new drugs to the Marketed Health', 'Products Directorate (MHPD) within 15 days of first notification. This regulation applies', 'to marketed drugs, and used as directed per the Canadian prescribing information,', 'including those drugs used in Phase IV (non CTA filed) clinical trials.', 'Adverse event (AE): Any untoward medical occurrence in a patient or clinical', 'investigation subject administered a pharmaceutical product and which does not', 'necessarily have to have a causal relationship with this treatment. An AE can therefore', 'be any unfavourable and unintended sign (including an abnormal laboratory finding)', 'symptom or disease (new or exacerbated) temporally associated with the use of a', 'Medicinal Product. For a marketed Medicinal Product, this can also include failure', 'to produce expected benefits (i.e. lack of efficacy, with or without an adverse event),', 'In order for GSK to comply this Canadian regulatory requirement, Canadian investigators', 'are required to collect, record and report lack of efficacy events as per the table in', 'Appendix 4 Section 12.4.1.', \"All paper forms are required to be faxed to GSK Canada's Drug Safety department at\", 'PP', 'within 24 hrs of first awareness.', '7.4.2.', 'Pregnancy', 'Details of all pregnancies in female subjects will be collected after the start of', 'Screening and until the follow-up contact.', 'If a pregnancy is reported then the investigator should inform GSK within 2', 'weeks of learning of the pregnancy and should follow the procedures outlined in', 'Appendix 7.', '7.4.3.', 'Medical Device Incidents (Including Malfunctions)', 'Procedures for documenting medical device incidents are provided in Appendix 6.', '7.4.4.', 'Electrocardiogram (ECG)', 'A Single 12-lead ECG will be obtained at Screening using an ECG machine provided by', 'the investigational site that automatically calculates the heart rate and measures PR, QRS,', 'QT, and QTc intervals.', '57']['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'The 12-lead ECG measurement and rhythm strip (10 seconds) will be obtained before', 'spirometry testing. ECG measurement should be obtained after subjects have rested for', 'approximately 5 minutes then the subjects should be placed in the supine position for the', 'ECG measurements. An ECG is only required at Screening Visit 1 for eligibility', 'assessment only.', 'The investigator, a designated sub-investigator, or other appropriately trained site', 'personnel will be responsible for performing and interpreting the 12-lead ECG at', 'Screening Visit 1. The investigator must provide his/her dated signature on the original', 'paper tracing, attesting to the authenticity of the ECG machine interpretation.', '7.5.', 'Genetics', 'Information regarding genetic research is included in Appendix 3', '8.', 'DATA MANAGEMENT', 'For this study subject data will be entered into GSK defined CRFs, transmitted', 'electronically to GSK or designee and combined with data provided from other', 'sources in a validated data system.', 'Management of clinical data will be performed in accordance with applicable', 'GSK standards and data cleaning procedures to ensure the integrity of the data,', 'e.g., removing errors and inconsistencies in the data.', 'Adverse events and concomitant medications terms will be coded using MedDRA', '(Medical Dictionary for Regulatory Activities) and an internal validated', 'medication dictionary, GSKDrug.', 'CRFs (including queries and audit trails) will be retained by GSK, and copies will', 'be sent to the investigator to maintain as the investigator copy. Subject initials', 'will not be collected or transmitted to GSK according to GSK policy.', '9.', 'STATISTICAL CONSIDERATIONS AND DATA', 'ANALYSES', '9.1.', 'Hypotheses', 'The primary purpose of this study is to demonstrate improvements in lung function for', 'subjects treated with UMEC/VI compared with UMEC for 24 weeks.', 'The primary endpoint is change from baseline in trough FEV1 at Week 24.', 'The null hypothesis is no difference between treatment groups (HO: T - S = 0), with', 'the alternative hypothesis that there is a difference between treatment groups (H1: T -', 'S # 0), where T is the mean change from baseline for UMEC/VI and S is the mean', 'change from baseline for UMEC.', '58']\n\n###\n\n", "completion": "END"}